On April 17, 2014 Chugai Pharmaceutical announced that it will launch the anti-HER2 antibody-tubulin polymerization inhibitor conjugate Kadcyla Intravenous Infusion 100 mg and 160 mg for the indication of HER2-positive inoperable or recurrent breast cancer on April 18, 2014 (Press release Chugai, APR 17, 2014, View Source [SID:1234500434]). Kadcyla received a manufacturing and marketing approval on September 20, 2013 and was listed on the National Health Insurance (NHI) reimbursement price list on April 17, 2014.